S&P 500   4,576.17 (+0.03%)
DOW   35,785.50 (+0.08%)
QQQ   381.04 (+0.51%)
AAPL   149.36 (+0.03%)
MSFT   319.77 (+3.12%)
FB   314.88 (-0.29%)
GOOGL   2,844.76 (+2.10%)
TSLA   1,055.31 (+3.62%)
AMZN   3,402.35 (+0.78%)
NVDA   246.09 (-0.44%)
BABA   170.97 (+0.58%)
NIO   40.99 (+1.28%)
CGC   13.22 (+0.38%)
GE   105.19 (-2.09%)
AMD   124.52 (+1.29%)
MU   67.79 (-1.67%)
T   25.30 (-0.28%)
F   15.72 (-1.38%)
ACB   7.04 (+0.14%)
DIS   170.62 (-0.83%)
PFE   43.14 (-0.96%)
BA   209.27 (-0.26%)
AMC   36.14 (+0.25%)
S&P 500   4,576.17 (+0.03%)
DOW   35,785.50 (+0.08%)
QQQ   381.04 (+0.51%)
AAPL   149.36 (+0.03%)
MSFT   319.77 (+3.12%)
FB   314.88 (-0.29%)
GOOGL   2,844.76 (+2.10%)
TSLA   1,055.31 (+3.62%)
AMZN   3,402.35 (+0.78%)
NVDA   246.09 (-0.44%)
BABA   170.97 (+0.58%)
NIO   40.99 (+1.28%)
CGC   13.22 (+0.38%)
GE   105.19 (-2.09%)
AMD   124.52 (+1.29%)
MU   67.79 (-1.67%)
T   25.30 (-0.28%)
F   15.72 (-1.38%)
ACB   7.04 (+0.14%)
DIS   170.62 (-0.83%)
PFE   43.14 (-0.96%)
BA   209.27 (-0.26%)
AMC   36.14 (+0.25%)
S&P 500   4,576.17 (+0.03%)
DOW   35,785.50 (+0.08%)
QQQ   381.04 (+0.51%)
AAPL   149.36 (+0.03%)
MSFT   319.77 (+3.12%)
FB   314.88 (-0.29%)
GOOGL   2,844.76 (+2.10%)
TSLA   1,055.31 (+3.62%)
AMZN   3,402.35 (+0.78%)
NVDA   246.09 (-0.44%)
BABA   170.97 (+0.58%)
NIO   40.99 (+1.28%)
CGC   13.22 (+0.38%)
GE   105.19 (-2.09%)
AMD   124.52 (+1.29%)
MU   67.79 (-1.67%)
T   25.30 (-0.28%)
F   15.72 (-1.38%)
ACB   7.04 (+0.14%)
DIS   170.62 (-0.83%)
PFE   43.14 (-0.96%)
BA   209.27 (-0.26%)
AMC   36.14 (+0.25%)
S&P 500   4,576.17 (+0.03%)
DOW   35,785.50 (+0.08%)
QQQ   381.04 (+0.51%)
AAPL   149.36 (+0.03%)
MSFT   319.77 (+3.12%)
FB   314.88 (-0.29%)
GOOGL   2,844.76 (+2.10%)
TSLA   1,055.31 (+3.62%)
AMZN   3,402.35 (+0.78%)
NVDA   246.09 (-0.44%)
BABA   170.97 (+0.58%)
NIO   40.99 (+1.28%)
CGC   13.22 (+0.38%)
GE   105.19 (-2.09%)
AMD   124.52 (+1.29%)
MU   67.79 (-1.67%)
T   25.30 (-0.28%)
F   15.72 (-1.38%)
ACB   7.04 (+0.14%)
DIS   170.62 (-0.83%)
PFE   43.14 (-0.96%)
BA   209.27 (-0.26%)
AMC   36.14 (+0.25%)
NASDAQ:HBIO

Harvard Bioscience Stock Forecast, Price & News

$7.14
+0.05 (+0.71 %)
(As of 10/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.03
$7.23
50-Day Range
$6.49
$8.47
52-Week Range
$3.07
$8.75
Volume88,220 shs
Average Volume216,620 shs
Market Capitalization$291.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.75
30 days | 90 days | 365 days | Advanced Chart
Receive HBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.


Harvard Bioscience logo

About Harvard Bioscience

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:HBIO
CUSIP
41690610
Employees
444
Year Founded
N/A

Sales & Book Value

Annual Sales
$102.10 million
Cash Flow
$0.28 per share
Book Value
$1.97 per share

Profitability

Net Income
$-7.81 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$291.05 million
Next Earnings Date
11/3/2021 (Confirmed)
Optionable
Optionable

MarketRank

Overall MarketRank

2.39 out of 5 stars

Computer And Technology Sector

173rd out of 869 stocks

Analytical Instruments Industry

5th out of 30 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -












Harvard Bioscience (NASDAQ:HBIO) Frequently Asked Questions

Is Harvard Bioscience a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Harvard Bioscience stock.
View analyst ratings for Harvard Bioscience
or view top-rated stocks.

What stocks does MarketBeat like better than Harvard Bioscience?

Wall Street analysts have given Harvard Bioscience a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Harvard Bioscience wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Harvard Bioscience's next earnings date?

Harvard Bioscience is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Harvard Bioscience
.

How can I listen to Harvard Bioscience's earnings call?

Harvard Bioscience will be holding an earnings conference call on Wednesday, November 3rd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) released its quarterly earnings data on Thursday, August, 5th. The medical instruments supplier reported $0.04 EPS for the quarter, beating the consensus estimate of $0.03 by $0.01. The medical instruments supplier had revenue of $29.20 million for the quarter, compared to analyst estimates of $27.40 million. Harvard Bioscience had a negative net margin of 2.51% and a positive trailing twelve-month return on equity of 8.03%.
View Harvard Bioscience's earnings history
.

How has Harvard Bioscience's stock price been impacted by Coronavirus (COVID-19)?

Harvard Bioscience's stock was trading at $2.47 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HBIO shares have increased by 189.1% and is now trading at $7.14.
View which stocks have been most impacted by COVID-19
.

What guidance has Harvard Bioscience issued on next quarter's earnings?

Harvard Bioscience updated its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $114.35 million-$117.42 million, compared to the consensus revenue estimate of $115.29 million.

What price target have analysts set for HBIO?

3 equities research analysts have issued 12 month price objectives for Harvard Bioscience's stock. Their forecasts range from $9.00 to $9.00. On average, they anticipate Harvard Bioscience's share price to reach $9.00 in the next year. This suggests a possible upside of 26.1% from the stock's current price.
View analysts' price targets for Harvard Bioscience
or view top-rated stocks among Wall Street analysts.

Who are Harvard Bioscience's key executives?

Harvard Bioscience's management team includes the following people:
  • James W. Green, Chairman, President & Chief Executive Officer
  • Kenneth F. Olson, COO, Senior VP-Global Operations & Engineering
  • Michael A. Rossi, Chief Financial Officer
  • Don Stewart, Vice President-North Americas & APAC Sales
  • Ryan Wallace, Vice President-Global Sales, Preclinical Systems

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

What is Harvard Bioscience's stock symbol?

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

Who are Harvard Bioscience's major shareholders?

Harvard Bioscience's stock is owned by a number of institutional and retail investors. Top institutional investors include Hillsdale Investment Management Inc. (0.99%), Strs Ohio (0.24%), Assenagon Asset Management S.A. (0.14%) and Triton Wealth Management PLLC (0.11%). Company insiders that own Harvard Bioscience stock include Alan I Edrick, Bertrand Loy, James W Green, James W Green and Value Fund Lp Palogic.
View institutional ownership trends for Harvard Bioscience
.

Which institutional investors are selling Harvard Bioscience stock?

HBIO stock was sold by a variety of institutional investors in the last quarter, including Hillsdale Investment Management Inc., and Strs Ohio.
View insider buying and selling activity for Harvard Bioscience
or view top insider-selling stocks.

Which institutional investors are buying Harvard Bioscience stock?

HBIO stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., and Triton Wealth Management PLLC. Company insiders that have bought Harvard Bioscience stock in the last two years include Alan I Edrick, Bertrand Loy, James W Green, and Value Fund Lp Palogic.
View insider buying and selling activity for Harvard Bioscience
or or view top insider-buying stocks.

How do I buy shares of Harvard Bioscience?

Shares of HBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harvard Bioscience's stock price today?

One share of HBIO stock can currently be purchased for approximately $7.14.

How much money does Harvard Bioscience make?

Harvard Bioscience has a market capitalization of $291.05 million and generates $102.10 million in revenue each year. The medical instruments supplier earns $-7.81 million in net income (profit) each year or $0.07 on an earnings per share basis.

How many employees does Harvard Bioscience have?

Harvard Bioscience employs 444 workers across the globe.

What is Harvard Bioscience's official website?

The official website for Harvard Bioscience is www.harvardbioscience.com.

Where are Harvard Bioscience's headquarters?

Harvard Bioscience is headquartered at 84 OCTOBER HILL RD, HOLLISTON MA, 01746.

How can I contact Harvard Bioscience?

Harvard Bioscience's mailing address is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. The medical instruments supplier can be reached via phone at (508) 893-8999 or via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.